Cellectar Biosciences and ITM Enter Supply Agreement for GMP-Grade Actinium-225
Supports Clinical Development of CLR 121225, Actinium-Labeled Compound for the Treatment of Solid TumorsFLORHAM PARK, N.J. and GARCHING, Germany and...
Pharmaceutical
Cosmos Health Expands Presence in the $7 Billion GCC Nutraceuticals Market, Signs Distribution Agreement with Scientific Pharmacy for Sky Premium Life in Oman, Including Initial Purchase Order of 42,000 Units
CHICAGO, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Cosmos Health Inc. (“Cosmos Health” or the “Company”) (NASDAQ:COSM), a diversified, vertically integrated global...
Biodesix Announces One-for-Twenty Reverse Stock Split
LOUISVILLE, Colo., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Biodesix, Inc. (Nasdaq: BDSX) (“Biodesix” or the “Company”), a leader in personalized...
Amneal Receives U.S. FDA Approval of Sodium Oxybate Oral Solution
Expands Amneal’s Affordable Medicines portfolio and broadens patient accessBRIDGEWATER, N.J, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Amneal Pharmaceuticals, Inc. (“Amneal”...
Enlivex CEO Issues Letter to Shareholders Outlining Strategic Roadmap Following Positive Phase IIa Allocetra™ Results
Allocetra™ demonstrated statistically significant and clinically meaningful improvements in pain and function in Phase IIa trial in primary osteoarthritis patients Six-month...
FOXO TECHNOLOGIES INC. ANNOUNCES ACQUISITION AGREEMENT TO ACQUIRE VECTOR BIOSOURCE INC.
WEST PALM BEACH, FL, Sept. 11, 2025 (GLOBE NEWSWIRE) -- FOXO Technologies Inc. (OTC: FOXO) (the “Company”), announces that it has signed a...
Maze Therapeutics Announces Oversubscribed $150.0 Million Private Placement
SOUTH SAN FRANCISCO, Calif., Sept. 11, 2025 (GLOBE NEWSWIRE) -- Maze Therapeutics, Inc. (Nasdaq: MAZE), a clinical-stage biopharmaceutical company developing...
Maze Therapeutics Announces Positive First-in-Human Results from Phase 1 Trial of MZE782, Establishing Proof of Mechanism for a Potent, Oral SLC6A19 Inhibitor with Potential to Treat Phenylketonuria (PKU) and Chronic Kidney Disease (CKD)
Phase 1 data in healthy volunteers exceed expectations and support best-in-class potential, enabling Phase 2 advancement for both intended indications...
Metsera to Present Research Highlighting its Next-Generation Obesity Portfolio at the 61st EASD Annual Meeting
NEW YORK, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Metsera, Inc. (Nasdaq: MTSR), a clinical-stage biopharmaceutical company accelerating the next generation...
A Landmark Pivotal Study Applying Precision Medicine to Psychiatry with Denovo’s DB104 (liafensine) for Treatment-Resistant Depression Published in JAMA Psychiatry
The study represents the first successful prospective genetic biomarker-guided drug trial in psychiatrySAN DIEGO, Sept. 11, 2025 (GLOBE NEWSWIRE) --...
RadioMedix and Vect-Horus Announce First Patient Dosed in Exploratory Clinical Study of 203Pb-RMX-VH-PIB for Glioblastoma Multiforme and Pancreatic Ductal Adenocarcinoma
Marks a significant milestone in ongoing collaboration between RadioMedix and Vect-Horus to advance innovative Theranostic radiopharmaceuticals to address unmet needs...
GenVivo Strengthens Oncology Leadership with Appointment of Noriyuki Kasahara, M.D., Ph.D., as Chief Scientific Officer
Scientific Advisory Board member, Dr. Noriyuki Kasahara, appointed Chief Scientific Officer of GenVivo, to accelerate the achievement of major clinical...
Bioxodes positive Phase 2a stroke data show breakthrough potential of innovative therapeutic candidate BIOX-101
Safety endpoint met, with encouraging signs of efficacy in trial with 23 patients suffering from intracerebral hemorrhage (ICH)Findings suggest BIOX-101...
Scancell reports Business Update and Financial Results for the Year Ended 30 April 2025
NOTTINGHAM, United Kingdom, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Scancell Holdings plc (AIM: SCLP), the developer of ImmunoBody® and Moditope®...
LB Pharmaceuticals Announces Pricing of its Upsized Initial Public Offering
NEW YORK, Sept. 10, 2025 (GLOBE NEWSWIRE) -- LB Pharmaceuticals Inc (“LB Pharmaceuticals”) today announced the pricing of its upsized initial...
Crinetics Pharmaceuticals Announces September 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
SAN DIEGO, Sept. 10, 2025 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on September 10, 2025,...
Luminous Global Announces 4th Annual Light Up the Night: “The Enchanted Garden” to Benefit the Luminous Advocacy Project
An evening of candlelight, music, and advocacy at the Mayfair House Hotel & Garden to support early breast cancer detection...
Hemogenyx Pharmaceuticals PLC Announces Invitation to Participate at DCNY Summit
Hemogenyx Pharmaceuticals Invited to Participate at DCNY Summit LONDON, UK / ACCESS Newswire / September 11, 2025 / Hemogenyx Pharmaceuticals...
Champions Oncology to Announce First Quarter Financial Results on Monday, September 15, 2025
HACKENSACK, NJ / ACCESS Newswire / September 10, 2025 / Champions Oncology, Inc. (Nasdaq:CSBR), a global preclinical and clinical research...
AGFA HealthCare Strengthens Market Position in KLAS Enterprise Imaging Report 2025
CARLSTADT, NJ / ACCESS Newswire / September 10, 2025 / AGFA HealthCare has been recognized by KLAS Research for significant...